G
GEN
vs
W
WIG20
Over the past 12 months, GEN has underperformed WIG20, delivering a return of +1% compared to the WIG20's +33% growth.
Stocks Performance
GEN vs WIG20
Performance By Year
GEN vs WIG20
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Genomed SA
Glance View
Genomed SA engages in the provision of medical diagnostic services. The company is headquartered in Warsaw, Woj. Mazowieckie. The company went IPO on 2011-05-30. The company develops molecular diagnostics based on deoxyribonucleic acid (DNA) sequencing, with a special focus on the Next Generation Sequencing (NGS) method. The Company’s offer includes the analysis of gene mutations responsible for over 150 congenital diseases, such as infertility, predisposition to cancer, cystic fibrosis (CF), Alzheimer's disease, hearing loss, coeliac disease, cardiomyopathy and obesity, among others. The Company’s activities are directed toward introducing genomic technology to personalized medicine and creating a clinic offering gene treatments. The firm also provides diverse DNA sequencing, analysis and synthesis services for research and the biotechnological market.
